drugset
drugset / Trial / NCT06341894

Efficacy and Safety of Dalpiciclib With Endocrine Therapy as Adjuvant Treatment in HR+/ HER2- Early Breast Cancer

NCT06341894 ↗

Phase 2 Recruiting 1163 enrolled The First Affiliated Hospital with Nanjing Medical University
NaSingle-groupOpen-labelTreatment

Summary

The investigator conduct a phase II multi-center, open-label trial to evaluate efficacy and safety of dalpiciclib with endocrine therapy as adjuvant treatment in patients with medium /high risk hormone receptor-positive, HER2-negative Early Breast Cancer.

Timeline

Start
2023-11-17
Primary completion
2027-06
Completion
2029-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Dalpiciclib Small molecule 100 mg Oral
Background Fulvestrant Small molecule — —

Indications

female breast carcinoma